#besponsa

BESPONSA (Mechanism of Action)

In this article, we will discuss BESPONSA (Mechanism of Action). So, let’s get started. Mechanism of ActionInotuzumab ozogamicin is a CD22-directed antibody-drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of…

In this article, we will discuss BESPONSA and Hepatotoxicity. So, let’s get started. Hepatotoxicity, Including Hepatic Veno-occlusive Disease (VOD) (also known as Sinusoidal Obstruction Syndrome) Inform patients that liver problems, including severe, life-threatening, or fatal VOD, and increases in liver tests may develop during BESPONSA treatment. Inform patients that they should seek…

In this article, we will discuss BESPONSA and Myelosuppression. So, let’s get started. Myelosuppression Inform patients that decreased blood counts, which may be life-threatening, may develop during BESPONSA treatment and that complications associated with decreased blood counts may includeinfections, which may be life-threatening or fatal, and bleeding/hemorrhage events. Inform patients that…

BESPONSA and Infusion Related Reactions

In this article, we will discuss BESPONSA and Infusion Related Reactions. So, let’s get started. Infusion Related Reactions In the INO-VATE ALL trial, infusion related reactions were observed in patients who received BESPONSA. Infusion related reactions (all Grade 2) were reported in 4/164 patients (2%). Infusion related reactions generally occurred in Cycle 1 shortly after the end of the…

BESPONSA (Mechanism of Action)

In this article, we will discuss BESPONSA (Mechanism of Action). So, let’s get started. Mechanism of ActionInotuzumab ozogamicin is a CD22-directed antibody-drug conjugate (ADC). Inotuzumab recognizes human CD22. The small molecule, N-acetyl-gamma-calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of…

In this article, we will discuss BESPONSA (Dosage Overview). So, let’s get started. IndicationsBESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).DosageRecommended Dosage• Pre-medicate before each dose.• For the first cycle, the recommended total dose of BESPONSA for all patients is 1.8 mg/m² per cycle, administered…

Top Pharma News of the Week

Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine

August 16, 2017

Amgen has announced that the New England Journal of Medicine (NEJM) published results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular…

Top Pharma News of the Week

Seattle Genetics gets a PhIII win for Adcetris

June 26, 2017

Seattle Genetics says that its flagship therapy, Adcetris, combined with a trio of standard drugs beat a 4-drug mainstay cocktail therapy in frontline Hodgkin disease for modified progression-free survival over a lengthy two-year stretch. The Adcetris package excluded bleomycin, which has been linked to a higher rate of lung toxicity…